Lun - Ven 8:00 - 17:00

Biodiversité

Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse

Education environnementale
Education environnementale

L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.

Ecotourisme
Ecotourisme

L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.

Développement Communautaire
Développement Communautaire

Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.

ODDB ONG

50mg Sildenafil Citrate Tablet

Sildenafil > sildenafil citrate tablets 50 mg


( 5.1)Use in pulmonary veno-occlusive disease (PVOD) may cause pulmonary edema and is not recommended.

6.1 Clinical Trials Experience

Pediatric Patients (1 to 17 Years old) Sildenafil tablets are indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underly improvements in exercise [ see Clinical Studies ( 14) ]. 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage in AdultsOral DosageThe recommended dosage of sildenafil tablets are 20 mg three times a day. Dose may be titrated to a maximum of 80 mg three times a day, if required, based on symptoms and tolerability [ see Clinical Studies ( 14) ].Although dose-response improvement in exercise ability was not observed in short-term studies in adults with PAH, the delay in clinical worsening with long-term use of sildenafil in Study A1481324 supports dosing up to a maximum of 80 mg three times a day [ see Clinical Studies ( 14) ].2.2 Recommended Dosage in Pediatric PatientsOral DosageThe recommended dosage in patients ≤20 kg is 10 mg three times a day.For pediatric patients 20 kg to 45 kg, the recommended dosage is 20 mg three times a day.For pediatric patients 45 kg and greater, the recommended dosage is 20 mg three times a day. A maximum dose in pediatric patients has sildenafil 45 mg chewable tablets not been identified. Based on the experience in adults, dose may be titrated to a maximum of 40 mg three times a day for pediatric patients >45 kg, if required, based on symptoms and tolerability [ see Clinical Studies ( 14) ].

Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately:

The recommended dosage of sildenafil tablets are 20 mg three times a day. Dose may be titrated to a maximum of 80 mg three times a day, if required, based on symptoms and tolerability [ see Clinical Studies ( 14) ]. Although dose-response improvement in exercise ability was not observed in short-term studies in adults with PAH, the delay in clinical worsening with long-term use of sildenafil in Study A1481324 supports dosing up to a maximum of 80 mg three times a day [ see Clinical Studies ( 14) ]. The recommended dosage in patients ≤20 kg is 10 mg three times a day. For pediatric patients 20 kg to 45 kg, the recommended dosage is 20 mg three times a day.

Interactions that increase your risk for side effects

For pediatric patients 45 kg and greater, the recommended dosage is 20 mg three times a day. 4 CONTRAINDICATIONS Sildenafil citrate is contraindicated in patients with:Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see Warnings and Precautions ( 5.1)] .Concomitant use of riociguat, a guanylate cyclase stimulator. Phosphodiesterase-5 (PDE5) inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat.Known hypersensitivity to sildenafil or any component of the tablet. Hypersensitivity, including anaphylactic reaction, anaphylactic shock and anaphylactoid reaction, has been reported in association with the use of sildenafil. Sildenafil citrate is contraindicated in patients with: Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see Warnings and Precautions ( 5.1)] . ( 5.2)Hearing or visual impairment: Seek medical attention if sudden decrease or loss of vision or hearing occurs. ( 5.4, 5.5)Pulmonary hypertension (PH) secondary to sickle cell disease: Sildenafil citrate may cause serious vaso-occlusive crises. ( 5.8)ADVERSE REACTIONSDRUG INTERACTIONSSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.Revised: 9/2023 • Adults: 20 mg three times a day Dose may be increased based on symptoms and tolerability. o ≤20 kg: 10 mg three times a day o 20 kg to 45 kg: 20 mg three times a day o >45 kg: 20 mg three times a day. Dose may be increased based on symptoms and tolerability.

Product Dosage Quantity + Bonus Price
Kamagra Soft Tabs100mg32 Pills120.11€ 114.39€
Viagra Generic25mg30 + 4 Pills47.97€ 45.69€
Viagra Generic100mg360 + 10 Pills330.21€ 314.49€
Viagra Generic150mg180 + 10 Pills236.46€ 225.20€
Viagra Generic25mg270 + 8 Pills184.26€ 175.49€
Viagra Generic50mg120 + 6 Pills129.64€ 123.47€
Viagra Generic100mg90 + 6 Pills129.02€ 122.88€
Viagra Generic50mg90 + 6 Pills107.37€ 102.26€
Viagra Generic100mg180 + 8 Pills199.37€ 189.88€
Kamagra100mg60 + 4 Pills201.34€ 191.75€

Vasodilation effects may be more common in patients with hypotension or on antihypertensive therapy.

Detection in biological fluids

Who should not take sildenafil?

Use in pulmonary veno-occlusive disease (PVOD) may cause pulmonary edema and is not recommended.

Country Approval Status Notable Regulations
USA Approved Prescription required
European Union Approved Prescription-only, monitoring recommended
Canada Approved Prescription only
India Approved Over the counter in some regions
Australia Approved Restricted to prescription use

Hearing or visual impairment: Seek medical attention if sudden decrease or loss of vision or hearing occurs. Pulmonary hypertension (PH) secondary to sickle cell disease: Sildenafil citrate may cause serious vaso-occlusive crises.

Warnings & Precautions

Phosphodiesterase-5 (PDE5) inhibitors, including sildenafil, may potentiate sildenafil citrate tablets 50mg the hypotensive effects of riociguat. Known hypersensitivity to sildenafil or any component of the tablet. 5 WARNINGS AND PRECAUTIONS 5.1 HypotensionSildenafil citrate has vasodilatory properties, resulting in mild and transient decreases in blood pressure. Before prescribing sildenafil tablets, carefully consider whether patients with certain underlying conditions could be adversely affected by such vasodilatory effects (e.g., patients on antihypertensive therapy or with resting hypotension [blood pressure less than 90/50], fluid depletion, severe left ventricular outflow obstruction, or autonomic dysfunction). Monitor blood pressure when co-administering blood pressure lowering drugs with sildenafil citrate.5.2 Worsening Pulmonary Vascular Occlusive DiseasePulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD).

How does sildenafil work (mechanism of action)?

Since there are no clinical data on administration of sildenafil citrate to patients with veno-occlusive disease, administration of sildenafil citrate to such patients is not recommended. Should signs of pulmonary edema occur when sildenafil citrate is administered, consider the possibility of associated PVOD.5.3 EpistaxisThe incidence of epistaxis was 13% in patients taking sildenafil citrate with PAH secondary to CTD. This effect was not seen in idiopathic PAH (sildenafil 3%, placebo 2%) patients. The incidence of epistaxis was also higher in sildenafil-treated patients with a concomitant oral vitamin K antagonist (9% versus 2% in those not treated with concomitant vitamin K antagonist).The safety of sildenafil citrate is unknown in patients with bleeding disorders or active peptic ulceration.5.4 Visual LossWhen used to treat erectile dysfunction, non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported postmarketing in temporal association with the use of PDE-5 inhibitors, including sildenafil. Most patients had underlying anatomic or vascular risk factors for developing NAION, including low cup to disc ratio (“crowded disc”).Advise patients to seek immediate medical attention in the event of a sudden loss of vision in one or both eyes while taking sildenafil citrate.There are no controlled clinical data on the safety or efficacy of sildenafil citrate in patients with retinitis pigmentosa, a minority of whom have genetic disorders of retinal phosphodiesterases.

IV Administration

Therefore, use of sildenafil citrate in patients with retinitis pigmentosa is not recommended.5.5 Hearing LossCases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in temporal association with the use of PDE-5 inhibitors, including sildenafil citrate. In some of the cases, medical conditions and other factors were reported that may have played a role. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of sildenafil citrate, to the patient's underlying risk factors for hearing loss, a combination of these factors, or to other factors.Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking PDE-5 inhibitors, including sildenafil tablets.5.6 Combination with Other PDE-5 inhibitorsSildenafil is also marketed as VIAGRA ®. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Table of Contents FULL PRESCRIBING INFORMATION: CONTENTS*1 INDICATIONS AND USAGE2 DOSAGE AND ADMINISTRATION2.1 Recommended Dosage in Adults2.2 Recommended Dosage in Pediatric Patients3 DOSAGE FORMS AND STRENGTHS4 CONTRAINDICATIONS5 WARNINGS AND PRECAUTIONS5.1 Hypotension5.2 Worsening Pulmonary Vascular Occlusive Disease5.3 Epistaxis5.4 Visual Loss5.5 Hearing Loss5.6 Combination with Other PDE-5 inhibitors5.7 Priapism5.8 Vaso-occlusive Crisis in Patients with Pulmonary Hypertension Secondary to Sickle Cell Disease6 ADVERSE REACTIONS6.1 Clinical Trials Experience6.2 Postmarketing Experience7 DRUG INTERACTIONS8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy8.2 Lactation8.4 Pediatric Use8.5 Geriatric Use8.6 Patients with Hepatic Impairment8.7 Patients with Renal Impairment10 OVERDOSAGE11 DESCRIPTION12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action12.2 Pharmacodynamics12.3 Pharmacokinetics13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility14 CLINICAL STUDIES16 HOW SUPPLIED/STORAGE AND HANDLING17 PATIENT COUNSELING INFORMATION*Sections or sildenafil 20 mg prescription subsections omitted from the full prescribing information are not listed.

  • Sildenafil citrate was initially developed for hypertension and angina.
  • It was later discovered to be effective for erectile dysfunction.
  • The drug was approved by the FDA for ED treatment in 1998.

Sections or subsections omitted from the full prescribing information are not listed. 1 INDICATIONS AND USAGE AdultsSildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [ see Clinical Studies ( 14) ].Pediatric Patients (1 to 17 Years old)Sildenafil tablets are indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underly improvements in exercise [ see Clinical Studies ( 14) ]. Sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [ see Clinical Studies ( 14) ]. Pediatric Patients (1 to 17 Years old) Sildenafil tablets are indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underly improvements in exercise [ see Clinical Studies ( 14) ]. 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage in AdultsOral DosageThe recommended dosage of sildenafil tablets are 20 mg three times a day. Dose may be titrated to a maximum of 80 mg three times a day, if required, based on symptoms and tolerability [ see Clinical Studies ( 14) ].Although dose-response improvement in exercise ability was not observed in short-term studies in adults with PAH, the delay in clinical worsening with long-term use of sildenafil in Study A1481324 supports dosing up to a maximum of 80 mg three times a day [ see Clinical Studies ( 14) ].2.2 Recommended Dosage in Pediatric PatientsOral DosageThe recommended dosage in patients ≤20 kg is 10 mg three times a day.For pediatric patients 20 kg to 45 kg, the recommended dosage is 20 mg three times a day.For pediatric patients 45 kg and greater, the recommended dosage is 20 mg three times a day. A maximum dose in pediatric patients has sildenafil 45 mg chewable tablets not been identified. Based on the experience in adults, dose may be titrated to a maximum of 40 mg three times a day for pediatric patients >45 kg, if required, based on symptoms and tolerability [ see Clinical Studies ( 14) ]. The recommended dosage of sildenafil tablets are 20 mg three times a day. Dose may be titrated to a maximum of 80 mg three times a day, if required, based on symptoms and tolerability [ see Clinical Studies ( 14) ].

Product Description

Although dose-response improvement in exercise ability was not observed in short-term studies in adults with PAH, the delay in clinical worsening with long-term use of sildenafil in Study A1481324 supports dosing up to a maximum of 80 mg three times a day [ see Clinical Studies ( 14) ]. The recommended dosage in patients ≤20 kg is 10 mg three times a day. For pediatric patients 20 kg to 45 kg, the recommended dosage is 20 mg three times a day. For pediatric patients 45 kg and greater, the recommended dosage is 20 mg three times a day. 4 CONTRAINDICATIONS Sildenafil citrate is contraindicated in patients with:Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see Warnings and Precautions ( 5.1)] .Concomitant use of riociguat, a guanylate cyclase stimulator.

Before taking this medicine

Phosphodiesterase-5 (PDE5) inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat.Known hypersensitivity to sildenafil or any component of the tablet. Hypersensitivity, including anaphylactic reaction, anaphylactic shock and anaphylactoid reaction, has been reported in association with the use of sildenafil. Sildenafil citrate is contraindicated in patients with: Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see Warnings and Precautions ( 5.1)] .

Health And Lifestyle

( 5.1)Use in pulmonary veno-occlusive disease (PVOD) may cause pulmonary edema and is not recommended. ( 5.2)Hearing or visual impairment: Seek medical attention if sudden decrease or loss of vision or hearing occurs. ( 5.4, 5.5)Pulmonary hypertension (PH) secondary to sickle cell disease: Sildenafil citrate may cause serious vaso-occlusive crises. ( 5.8)ADVERSE REACTIONSDRUG INTERACTIONSSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.Revised: 9/2023 • Adults: 20 mg three times a day Dose may be increased based on symptoms and tolerability. o ≤20 kg: 10 mg three times a day o 20 kg to 45 kg: 20 mg three times a day o >45 kg: 20 mg three times a day.

Raynaud's phenomenon

Dose may be increased based on symptoms and tolerability. Vasodilation effects may be more common in patients with hypotension or on antihypertensive therapy. Use in pulmonary veno-occlusive disease (PVOD) may cause pulmonary edema and is not recommended. Hearing or visual impairment: Seek medical attention if sudden decrease or loss of vision or hearing occurs. Pulmonary hypertension (PH) secondary to sickle cell disease: Sildenafil citrate may cause serious vaso-occlusive crises.

Does sildenafil cause different side effects in females?

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Table of Contents FULL PRESCRIBING INFORMATION: CONTENTS*1 INDICATIONS AND USAGE2 DOSAGE AND ADMINISTRATION2.1 Recommended Dosage in Adults2.2 Recommended Dosage in Pediatric Patients3 DOSAGE FORMS AND STRENGTHS4 CONTRAINDICATIONS5 WARNINGS AND PRECAUTIONS5.1 Hypotension5.2 Worsening Pulmonary Vascular Occlusive Disease5.3 Epistaxis5.4 Visual Loss5.5 Hearing Loss5.6 Combination with Other PDE-5 inhibitors5.7 Priapism5.8 Vaso-occlusive Crisis in Patients with Pulmonary Hypertension Secondary to Sickle Cell Disease6 ADVERSE REACTIONS6.1 Clinical Trials Experience6.2 Postmarketing Experience7 DRUG INTERACTIONS8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy8.2 Lactation8.4 Pediatric Use8.5 Geriatric Use8.6 Patients with Hepatic Impairment8.7 Patients with Renal Impairment10 OVERDOSAGE11 DESCRIPTION12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action12.2 Pharmacodynamics12.3 Pharmacokinetics13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility14 CLINICAL STUDIES16 HOW SUPPLIED/STORAGE AND HANDLING17 PATIENT COUNSELING INFORMATION*Sections or sildenafil 20 mg prescription subsections omitted from the full prescribing information are not listed. Sections or subsections omitted from the full prescribing information are not listed. 1 INDICATIONS AND USAGE AdultsSildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [ see Clinical Studies ( 14) ].Pediatric Patients (1 to 17 Years old)Sildenafil tablets are indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underly improvements in exercise [ see Clinical Studies ( 14) ]. Sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [ see Clinical Studies ( 14) ]. Phosphodiesterase-5 (PDE5) inhibitors, including sildenafil, may potentiate sildenafil citrate tablets 50mg the hypotensive effects of riociguat. Known hypersensitivity to sildenafil or any component of the tablet. 5 WARNINGS AND PRECAUTIONS 5.1 HypotensionSildenafil citrate has vasodilatory properties, resulting in mild and transient decreases in blood pressure. Before prescribing sildenafil tablets, carefully consider whether patients with certain underlying conditions could be adversely affected by such vasodilatory effects (e.g., patients on antihypertensive therapy or with resting hypotension [blood pressure less than 90/50], fluid depletion, severe left ventricular outflow obstruction, or autonomic dysfunction).

  • Sildenafil citrate 50 mg is used to treat erectile dysfunction in men.
  • The typical starting dose is 50 mg taken about one hour before activity.
  • It should not be used more than once per 24 hours.

Monitor blood pressure when co-administering blood pressure lowering drugs with sildenafil citrate.5.2 Worsening Pulmonary Vascular Occlusive DiseasePulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of sildenafil citrate to patients with veno-occlusive disease, administration of sildenafil citrate to such patients is not recommended. Should signs of pulmonary edema occur when sildenafil citrate is administered, consider the possibility of associated PVOD.5.3 EpistaxisThe incidence of epistaxis was 13% in patients taking sildenafil citrate with PAH secondary to CTD. This effect was not seen in idiopathic PAH (sildenafil 3%, placebo 2%) patients. The incidence of epistaxis was also higher in sildenafil-treated patients with a concomitant oral vitamin K antagonist (9% versus 2% in those not treated with concomitant vitamin K antagonist).The safety of sildenafil citrate is unknown in patients with bleeding disorders or active peptic ulceration.5.4 Visual LossWhen used to treat erectile dysfunction, non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported postmarketing in temporal association with the use of PDE-5 inhibitors, including sildenafil. Most patients had underlying anatomic or vascular risk factors for developing NAION, including low cup to disc ratio (“crowded disc”).Advise patients to seek immediate medical attention in the event of a sudden loss of vision in one or both eyes while taking sildenafil citrate.There are no controlled clinical data on the safety or efficacy of sildenafil citrate in patients with retinitis pigmentosa, a minority of whom have genetic disorders of retinal phosphodiesterases. Therefore, use of sildenafil citrate in patients with retinitis pigmentosa is not recommended.5.5 Hearing LossCases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in temporal association with the use of PDE-5 inhibitors, including sildenafil citrate. In some of the cases, medical conditions and other factors were reported that may have played a role. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of sildenafil citrate, to the patient's underlying risk factors for hearing loss, a combination of these factors, or to other factors.Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking PDE-5 inhibitors, including sildenafil tablets.5.6 Combination with Other PDE-5 inhibitorsSildenafil is also marketed as VIAGRA ®.

 Singes à ventre roux

10+

Années d'expérience

ODDB ONG

Domaines d'interventions

Les objectifs que
nous poursuivons

Dans le cadre de notre stratégie, nous menons des actions locales dans les différentes écorégions cruciales, en visant des objectifs globaux.

Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.

Biodiversité

Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse

En savoir plus
Education environnementale

L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.

En savoir plus
Ecotourisme

L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.

En savoir plus
Développement Communautaire

Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.

En savoir plus
ODDB ONG

Nos Projets

ODDB-ONG agit pour l'environnement et le mieux-être des communautés locales.

ODDB-ONG mène des actions écologiques pour soutenir les populations locales dans leurs efforts pour améliorer leur bien-être et celui de leur environnement.

Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.

Merci de soutenir nos projets

Votre don nous permet d’agir, merci !

ODDB ONG

Question à nous poser

Une question d'ordre général ?

La biodiversité fait référence à la variété et à la diversité de la vie sur Terre, y compris toutes les espèces d'animaux, de plantes, de micro-organismes et les écosystèmes dans lesquels ils vivent. Cela englobe la richesse génétique au sein des espèces, la diversité des espèces elles-mêmes et la variété des habitats naturels. En résumé, la biodiversité représente la variété de la vie et des écosystèmes qui rendent notre planète unique et fonctionnelle.

Pour poursuivre nos actions pour la planète et en engager de nouvelles, nous sollicitons le soutien de tous. Chaque contribution est importante. Partagez nos campagnes, faites un don, devenez bénévole pour ODDB ONG et aidez-nous à préserver la nature.

Le logo du ODDB ONG est une marque internationale déposée et soumise au droit d'auteur. Toute utilisation ou reproduction est strictement interdite sans autorisation. Si vous souhaitez utiliser le logo dans le cadre d'un partenariat, veuillez écrire à l'adresse suivante. Pour toute autre utilisation, veuillez contacter l'adresse suivante.

Pour toute demande de stage, veuillez consulter régulièrement notre page dédiée au recrutement.

Pour commencer, il est essentiel d'adopter de bonnes habitudes quotidiennes : privilégier une alimentation équilibrée avec moins de protéines animales et favorisant les circuits courts, opter pour des modes de transport durables tels que les transports en commun ou le vélo, améliorer votre efficacité énergétique et votre utilisation numérique, et réduire la production de déchets. Toutes ces pratiques sont détaillées dans la section " Agir au quotidien".

Un accusé de réception vous est envoyé par mail pour vous confirmer la réception de votre dossier de candidature.

Les conséquences de la crise écologique sont manifestes : une agriculture en déclin, des plans d'eau épuisés, un accès difficile à l'eau douce et des forêts en difficulté pour préserver la biodiversité. Notre enjeu environnemental majeur est clair : l'urgence d'agir. Cette nécessité ne concerne plus seulement les générations futures, mais également la population actuelle, qui subit déjà les perturbations profondes engendrées par la crise écologique.
singe a ventre rouge
ODDB ONG

Galerie

Nos Actions En Image

Dendroaspis jamesoni
ODDB ONG
Dendroaspis jamesoni
Benin Potto (Perodicticus potto juju)
ODDB ONG
Benin Potto (Perodicticus potto juju)
Singe tantale (Chlorocebus aethiops tantalus)
ODDB ONG
Singe tantale (Chlorocebus aethiops tantalus)
Female Sitatunga with offspring (Tragelaphus spekii)
ODDB ONG
Female Sitatunga with offspring (Tragelaphus spekii)
Cercopithecus aethiops tantalus
ODDB ONG
Cercopithecus aethiops tantalus
Coucal noir (Centropus senegalensis)
ODDB ONG
Coucal noir (Centropus senegalensis)
Cercopithecus erythrogaster
ODDB ONG
Cercopithecus erythrogaster
Female sitatunga (Tragelaphus spekii)
ODDB ONG
Female sitatunga (Tragelaphus spekii)
Gnanhouizoun community forest, Ouémé valley
ODDB ONG
Gnanhouizoun community forest, Ouémé valley
chouette
ODDB ONG
chouette
Héron cendré (Ardea cinerea)
ODDB ONG
Héron cendré (Ardea cinerea)
Apercu de l'entrée du village Gnanhouizounmè Apercu de l'entrée du village Gnanhouizounmè Saison sèche
ODDB ONG
Apercu de l'entrée du village Gnanhouizounmè Apercu de l'entrée du village Gnanhouizounmè Saison sèche
Jacana à poitrine dorée (Actophilormis africana) Gnanhouizounmè_Bonou
ODDB ONG
Jacana à poitrine dorée (Actophilormis africana) Gnanhouizounmè_Bonou
Gnanhouizounmè au couché de soleil
ODDB ONG
Gnanhouizounmè au couché de soleil
Chamaeleo necasi
ODDB ONG
Chamaeleo necasi
Aigrette
ODDB ONG
Aigrette

Nos Statistiques

ODDB en chiffres

10+

10+

Années d'expérience

79

79Ha

de superficies reboisées

14K+

14K+

personnes sensibilisées

320

320

personnes autonomisées

151

151

Stagiaires et bénévoles formés pour suivi de la biodiversité

ODDB ONG

Nos Actualités

Actualités

Nos  Partenaires

Partenaires Techniques

little green guards Chester Zoo Institut des Tortues d'Afrique Conservatoire pour la Protection des Primates National Geographic

Partenaires Financiers

Primate Society of Great Britain SUCO INTERNATIONAL BENIN UP2GREEN The Rufford Foundation IKI